Loading...
•
Jun 30, 2025
Zimmer Biomet Q2 2025 Earnings Report
Zimmer Biomet reported strong sales growth and raised full-year EPS guidance.
Key Takeaways
Zimmer Biomet delivered solid Q2 2025 results with $2.077 billion in revenue and $152.8 million in net earnings. Growth was driven by increased sales in Hips and S.E.T. segments, especially in the U.S., as well as strategic initiatives including a major acquisition.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Zimmer Biomet raised its full-year 2025 adjusted EPS guidance and tightened its revenue growth range.
Positive Outlook
- Raised adjusted EPS guidance to $8.10 - $8.30
- Tightened constant currency revenue growth range to 6.2% - 7.2%
- Strong momentum in U.S. Knees and Hips portfolios
- SET business demonstrated double-digit growth
- Excitement around new AI-driven robotics from Monogram Technologies acquisition
Challenges Ahead
- Operating margin declined year-over-year
- Lower organic constant currency growth at 2.8%
- Ongoing restructuring and integration costs
- Slight decline in Tech/Data/Surgical segment
- Higher interest expense impacted earnings
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...